In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dealmaking Quarterly Statistics, Q2 2020

A Look At M&A And Alliance Activity Across The Biopharma, Medical Device And In Vitro Diagnostics Industries, April-June 2020

Executive Summary

During Q2 biopharmas reached $5.9bn in merger and acquisition value and drew in $44bn in potential deal value from alliances. Device company M&A values reached $159m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.4bn.

You may also be interested in...



Goldman Sachs Takes Holding In CRO Aragen Amid Outsourcing Impetus

Goldman Sachs backs CRO Aragen, which it believes is well placed to gain from the “secular trend” of an outsourcing uptick by biopharma. Aragen has a string of alliances and is also assisting with both vaccine and test kit development against SARS-CoV-2 for its customers.

Menarini Seals Stemline Merger

The purchase gives the Italian firm ownership of the blood cancer therapy Elzonris which is already approved in the US and attracted the attention of another potential acquirer before Menarini clinched the deal to buy Stemline. 

Novo Nordisk Fortifies Cardio-Renal Efforts With Corvidia Buy

Novo Nordisk is paying $725m to acquire the VC-backed US biotech, Corvidia Therapeutics and its promising Phase II candidate, ziltivekimab, for chronic kidney disease, but further payments could total more than $2bn.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

IV124564

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel